History of Marek's disease:
Marek's disease is a fatal lymphoproliferative disease in domesticated chickens (Gallus domesticus) with its inception in 1907 by a renowned veterinarian Dr. Joseph Marek at department of Royal Hungarian veterinary school in Budapest. Initially the disease was described as 'polyneuritis' while studying four adult cockerels, which were affected by paralysis of wings and legs. He noted thickening of sacral plexus and spinal routes which were infiltrated by mononuclear cells [1]. Vilhelm Ellerman and Olaf Bang, two Danish scientists in 1908 were the first to show that leukemia of fowl was transmissible by cell free filtrates. Peyton Rous in 1910 working in Newyork reported that sarcoma of fowl was also caused by a filterable agent [2]. Both of these later turned out to be avian retroviruses i.e. Avian leukosis and Rous sarcoma viruses but important factor was the evidence of virally-induced tumors in man and chicken Etiology: Marek's disease is one of the most ubiquitous avian infections and is identified among flocks worldwide. Every flock except for those maintained under strict pathogenfree conditions are presumed to be infected. Clinical disease is however not always apparent in flocks [1,6]. The etiological agent is alphaherpesvirus also called Gallid herpesvirus 2. Three serotypes recognized in which serotype 1and 2 designate virulent and avirulent chicken isolates and 3 are avirulent turkey herpesvirus. A classification system called 'neuropathotyping' is a statistical approach that was used to establish a new system of classification of Marek's disease virus on the basis of neurologic responses [7] . Serotype 1 comprise pathogenic virus and their attenuated variants; serotype 2 are a group of non-pathogenic virus isolated from chickens, and serotype 3 is the herpesvirus of turkeys (HVT) which has been used extensively as a vaccine against MD .All strains of chickens are susceptible to infection with MDV but genetic studies have shown that genes linked to the major histocompatibility (B) complex are associated with resistance to disease following infection with standard pathogenic strains [8] . Gallid herpesvirus 2, the causative agent is cell-associated in tumors and in all organs except in feather follicle where enveloped infectious virions egress from the body [9].
Epidemiology: The incidence of MD increased substantially from the 1930s to the 1950s with the expansion in poultry production and is found among flocks all over the world. By the 1960s MD caused significant problems with poultry health and welfare and a heavy financial burden on the poultry industry. Most chickens have antibodies to Marek's virus by the time they are mature, infection persists and virus is shed from follicles along with desquamated cells. This dander can remain infective for several months in dust and litter in poultry houses [10] . Congenital infection does not occur and chicks are protected by maternal antibodies for first few weeks of life [5,6,10] Epidemics involve sexually immature birds 2-5 months old, high mortality rate about 80% soon peaks and then decline.
[5] However the mortality rate may vary from 1% to 50% during the life span of chicken in the population. [9] The only significant factor with an effect on mortality from MD is rearing house pen. Because the pen within a rearing house can have a significant effect on mortality from MD, it is not unlikely that rearing house could also have a similar effect. The environment during the first 8 to 9 weeks of life is of greatest importance in determining the subsequent mortality from MD and the environment after this time had little or no influence. [11] Three factors are very important in determining whether infection leads to clinical disease are strain of virus, genetic constitution of host and age of host. . MD vaccine viruses establish a persistent infection which reduces early viraemia, after subsequent exposure to pathogenic strains, and protects against tumour formation and hence mortality so infection has no economic consequences [23] . However, importantly, MD vaccines do not prevent super-infection by challenge viruses. Multiplication of the virulent challenge virus and its shedding from feather tissues still occurs. Moreover there is incidence of vaccine failure due to certain factors as in Fig 1 [24] . This has two major consequences. Firstly, virulent virus shed by vaccinated birds is still oncogenic to non-vaccinated birds. Secondly, there is continued evolution of field viruses towards pathotypes of greater virulence [25] . BAC (bacterial artificial chromosomes) clones of an attenuated MDV strain, CVI988, have been used to investigate various gene functions for studying MDV biology and pathogenesis. Viruses derived from the BAC clones are stable after in vitro and in vivo passages and showed characteristics and growth kinetics similar to those of the parental virus. These viruses induced 100 percent protection against infection by the virulent strain RB1B, indicating that BACderived viruses could be used with efficacies similar to those of the parental CVI988 vaccines. The construction of the CVI988 BAC is a major step towards understanding the superior immunogenic features of CVI988 and provides the opportunity to exploit the power of BAC technology for generation of novel molecularly defined vaccines [26] .
Research on Marek's disease (MD) has accomplished a great number of success within the last 50 years, such as the development of the first most widely used anticancer vaccine around the world; the very efficient control of one of the most devastating diseases for the poultry; and the development of a technology that permits immunization of embryos against infectious poultry diseases. But in doing so the fact to be realized is that the vaccines that protect against the development of the disease do not stop the infection or transmission and are only a temporary solution that might drive the pathogen to higher virulence [27].
Fig 1.
Factors involved in vaccine failure [24] . 
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